US Government To Purchase Additional 1.4M Doses Of Merck's COVID-19 Pill

Loading...
Loading...
  • The U.S. government will buy another $1 billion worth of Merck & Co Inc MRK and partner Ridgeback Biotherapeutics' COVID-19 pills.
  • The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.
  • That brings the total secured courses to 3.1 million and worth $2.2 billion. 
  • Merck said the government has the right to buy 2 million more courses as part of the contract.
  • The FDA's Antimicrobial Drugs Advisory Committee will discuss the application for Molnupiravir on November 30.
  • Related: Merck, Ridgeback File For Emergency Use Nod For COVID-19 Antiviral.
  • Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end," said Frank Clyburn, president of Merck's human health business.
  • Read Next: Merck Ahead Of Pfizer In Talks With Europe For COVID-19 Pills: Reuters.
  • Price Action: MRK shares are up 0.71% at $$83.27 during the premarket session on the last check Tuesday.
Posted In: BiotechGovernmentNewsHealth CareContractsGeneralBriefsCOVID-19 Coronavirus
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...